Ipsen’s partner Roche announces that Taspoglutide meets its primary endpoint in the first phase III clinical trial

This article or press release has no online content. Please download the associated documents for more information.

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved. - 2021